Health AI Central
Share:
Peer-Reviewed Publication
Curr Med Res Opin2026;1-10.August 18, 2026Journal Article

Neoplastic findings after positive multi-target stool DNA testing in a large gastroenterology practice.

Timothy Ritter1, Rashmi Goyat2, Charles Owen3, Lucinda Van Anglen4, Paul Limburg2, Mallik Greene2
1GI Alliance Research, Southlake, TX, USA.
2Abbott, Madison, WI, USA.
3Iterative Health, Southlake, TX, USA.
4Healix, LLC, Sugar Land, TX, USA.
PubMed DOI

Abstract

BACKGROUND: Multi-target stool DNA (mt-sDNA) testing is a noninvasive colorectal cancer (CRC) screening option, but real-world data on follow-up colonoscopy (FU-CY) completion and findings after positive results are limited. AIM: To evaluate FU-CY completion and advanced neoplasia (AN) after positive mt-sDNA testing. METHODS: Electronic health record data from a convenience sample of adults aged…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free AccountSign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.